RFA-CA-23-023: Liver Cancer Collaborative Projects with the Liver Cirrhosis Network (U01 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $200,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on June 2, 2023.
From the official notice on Grants.gov, last changed March 30, 2023. Checked November 7, 2026.
- Award ceiling$200,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsOptional
- Funded byNCI
- Median yearly award$341,018
- Typical project length4 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-CA-23-023 were run by National Cancer Institute (NCI, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-23-023 in the NIH Guide.
Key dates
| Posted | March 30, 2023 |
|---|---|
| Deadline | June 2, 2023 |
| Archived by Grants.gov | July 8, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $341,018; it allows up to $200,000 per award.
- Most of the program's money (69% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to establish collaborations between liver cancer investigators and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-funded Liver Cirrhosis Network (LCN) members to advance our understanding of hepatocellular carcinoma (HCC) as the result of liver cirrhosis and its etiologic risks, development, progression, early diagnosis, and treatment. The funds available through this FOA will support new multidisciplinary liver cancer-specific collaborations between eligible liver cancer investigators and one or more of the NIDDK-funded LCN members. This structure is intended to maximize the effectiveness of the network by facilitating collaborative opportunities that enhance the scientific goals of the collaborating units and the LCN as a whole. Applicants selected for NCI funding will become members of the Liver Cirrhosis Network-Liver Cancer Collaboratory (LCN-LCa) Committee.
Funded under RFA-CA-23-023 so far
NIH funded 4 projects under RFA-CA-23-023 in fiscal 2023 to 2026, at 4 institutions. The median yearly award was $341,018.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Genetic and Environmental risk of NAFLD-related HCC In All Latinos: the GENIAL Study | University of Miami School of Medicine | 2026 | $164,823 |
| Molecular Mechanisms by which Statins Prevent and Reverse Hepatocellular Carcinoma | Stanford University | 2025 | $656,499 |
| Genomic and environmental drivers of HCC in Non-Hispanic Blacks: Nature and nurture | Icahn School of Medicine at Mount Sinai | 2025 | $682,915 |
| Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis | UT Southwestern Medical Center | 2025 | $628,059 |
Who has won Cancer Biology Research grants before
From fiscal 2021 to 2025, Cancer Biology Research (93.396) awarded $4.3 billion across 3,142 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 70 | $151 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 109 | $144 million |
| Sloan-Kettering Institute for Cancer Research | New York | 66 | $136 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 47 | $107 million |
| The Regents of the University of California, San Francisco | California | 64 | $95.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-23-023 still open?
No. It closed on June 2, 2023.
Who can apply for Liver Cancer Collaborative Projects with the Liver Cirrhosis Network (U01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Liver Cancer Collaborative Projects with the Liver Cirrhosis Network (U01 Clinical Trial Optional)?
Closed June 2, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $200,000 each.
Who has been funded under RFA-CA-23-023?
NIH RePORTER lists 4 projects funded under RFA-CA-23-023 in fiscal 2023 to 2026, at 4 institutions. The most were at University of Miami School of Medicine, Stanford University, Icahn School of Medicine at Mount Sinai.
Who has won Cancer Biology Research grants before?
The largest recipients over five fiscal years were The Trustees of Columbia University in the City of New York, The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research. The program made 3,142 awards worth $4.3 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)